Alcon Inc has demonstrated steady revenue growth over the past three years, rising nearly 10% cumulatively from 2023 to 2025. However, operating income data from the latest available period show a stark contraction, reflecting operational pressures or one-time impacts. The company’s capital allocation strategy balances robust free cash flow generation with shareholder returns via dividends and a completed significant share buyback program early 2026. Governance practices emphasize risk management and compliance, particularly in cybersecurity, while strategic M&A plans face uncertainty after the cancellation of the STAAR Surgical deal. Market watchers should focus on upcoming earnings and product pipeline updates as indicators of medium-term growth prospects.